Planegg/Martinsried (pta022/26.10.2022/17:48 UTC+2)
The Executive Management Board of Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology company focusing on the development of T-cell-based cancer therapies, today resolved to adjust the financial forecast for fiscal year 2022.
Due to the closing of the clinical trial with the product candidate MDG1011 in blood cancer as well as further savings, the forecast for research and development expenses is reduced from previously €11 – 15 m to a range of €9 – 11 m. Consequently, the forecast for earnings before interest, taxes, depreciation and amortization (EBITDA) improves from previously €3 – 5 m to €8 – 9 m.
The Company continues to expect revenues of €23 – 28 m in 2022 and is financed into Q4 2024 on the basis of current planning.
Lochhamer Straße 11
|Contact Person:||Medigene PR/IR|
|Phone:||+49 89 2000 3333 01|
|Stock Exchange(s):||Regulated Market in Frankfurt; Free Market in Berlin, Dusseldorf, Hamburg, Hannover, Munich, Stuttgart, Tradegate|